News Category
Coherence Neuro's $45 million Series A, led by Peter Thiel's Founders Fund and the OpenAI Startup Fund, will fund the first chronic human trial of its...
Adaptogenics Health Corp. is pursuing a three-pronged strategy in the peptide sector, combining supply infrastructure, proprietary therapeutics and in...
Neovii Pharmaceuticals is launching a pivotal Phase 2 study of ATLG in Type 1 Diabetes, supported by FDA Fast Track designation, and has named Salvato...
Annovis Bio's three presentations at the 2026 CTAD conference will showcase buntanetap's mechanism, Phase 3 trial design, and AI-driven blood-brain ba...
NeuroThera Labs has completed manufacturing and obtained European QP batch release certification for its SCI-110 investigational drug, enabling shipme...
VERAXA Biotech is implementing New Approach Methodologies across its preclinical research programs, aiming to improve the clinical relevance of its an...
VERAXA Biotech is advancing its BiTAC platform to improve the selectivity of antibody-based cancer therapies, potentially reducing toxicity while main...
A new scorecard from the Special Competitive Studies Project finds the United States still leads China in biotechnology but risks losing that edge by ...
SS Innovations International (NASDAQ: SSII) has launched Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, marking a signif...
Regentis Biomaterials has achieved a 400% increase in production yield for its GelrinC cartilage repair implant following European regulatory approval...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article, but the coverage highlights both...
Scinai Immunotherapeutics announced a more than 300% increase in committed CDMO orders to $8.1 million and $5.3 million in net financing proceeds, ext...
Bangladesh's major measles outbreak, with over 200,000 suspected cases, highlights the global risk of falling vaccination rates and serves as a cautio...
NanoViricides reports positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric trials for Ebola...
VERAXA Biotech is expanding its use of FDA-aligned New Approach Methodologies to generate more clinically relevant preclinical data while reducing ani...
Pentixapharm's Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism is reinforced by independent international data presented at EA...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article that highlighted promising but li...
A small German study's eight-year follow-up shows two-thirds of patients with aggressive brain tumors were still alive and 42% had no recurrence, unde...
TransCode Therapeutics will present updated Phase 1a clinical data for its lead candidate TTX-MC138 at the ESMO Congress 2026, a key event that could ...
Tonix Pharmaceuticals will present poster data on TONMYA for fibromyalgia at the 2026 IASP World Congress, highlighting the first new treatment approv...
A new study reveals that ISAba1-mediated amplification of the crp-osmC gene cluster enhances Acinetobacter baumannii's ability to colonize and survive...
Measles infections cause lasting immune vulnerabilities, making survivors susceptible to other infections, highlighting the need for increased vaccine...
Creative BioTherapeutics' nomination for the 2026 Prix Galien USA Best Startup award highlights its preclinical work on CBT300, an investigational bio...
HeartBeam's role in the EU-funded EXIT-CVD consortium and its leadership of the HEART-CHECK study could accelerate clinical validation of its portable...
Helus Pharma appoints Dr. Suresh Durgam, a veteran with over 20 years of CNS drug development experience, to its board, signaling a strategic push to ...
Tonix Pharmaceuticals will present its TNX-801 vaccine platform at the World Vaccine Congress Europe, highlighting its potential to address mpox and o...
MindMaze Therapeutics' home-based rehabilitation program with Vibra Healthcare tripled motor-training dose and improved functional outcomes, supportin...
Quantum BioPharma's FDA clearance to begin Phase 2 testing of Lucid-MS marks a significant step for a non-immunological approach to multiple sclerosis...
SS Innovations has submitted its response to the FDA's additional information request for the SSi Mantra surgical robotic system, moving the company c...
MindBio Therapeutics has finished manufacturing its next-generation AI-powered intoxication detection kiosk, marking a step toward a potential commerc...
MindBio Therapeutics has finished manufacturing its next-generation Edge AI Intoxication Detection Kiosk, moving its voice-based impairment screening ...
Retension Pharmaceuticals' upsized $45 million IPO will fund its Phase 2b trial of RTN-001 for uncontrolled hypertension and advance preparations for ...
VERAXA Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform, demonstrating significant tumor regression in a breast cancer...
A UK study reveals that clearing immune fog could stop lung cancer before diagnosis, potentially revolutionizing early intervention and spurring advan...
Scinai Immunotherapeutics' CDMO subsidiary signed a $5.1 million development and clinical manufacturing agreement with a Nasdaq-listed biopharma, driv...
VERAXA Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress, demonstrating significant tumor r...
Leksum's agreement with the Medical University of Vienna to prepare for Phase I/II trials of LK-ICU highlights a potential breakthrough for ICU-acquir...
Regentis Biomaterials will present at the 2026 ThinkEquity Conference, showcasing its GelrinC technology and progress toward commercialization, which ...
Newron Pharmaceuticals is reviewing FDA feedback on a clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial of evenamide, while enrol...
Lantern Pharma's upcoming presentation at the ThinkEquity Conference underscores the growing role of artificial intelligence in accelerating precision...
Helus Pharma's upcoming investor presentation on October 21 will showcase its Phase 3 depression treatment HLP003 and Phase 2 anxiety treatment HLP004...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel Lucid-MS multiple sclerosis treatment into Phase 2 execu...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could accelerate clinical advancement and cut animal testing by up to 95% for its ...
Nutriband's new patent application could extend protection for its AVERSA abuse-deterrent transdermal technology through 2046, reinforcing its leaders...
Lantern Pharma's Taiwan regulatory and IRB approvals for Part 2 of its Phase 2 HARMONIC trial of LP-300 could accelerate development of a targeted the...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Luc...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could dramatically reduce animal testing, cut costs, and speed up clinical develop...
XORTX Therapeutics is advancing its gout treatment XORLO through clinical and manufacturing milestones, aiming for an FDA New Drug Application in abou...
